FindTrial
Sign In

G-202

DRUG8 trials

Sponsors

GenSpera, Inc., Devalingam Mahalingam

Conditions

Advanced Adult Hepatocellular CarcinomaAdvanced Solid TumorsClear Cell Renal Cell CarcinomaGlioblastomaGlioblastoma MultiformeHepatocellular CarcinomaProstate Cancer.Prostatic Neoplasms

Phase 1

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
CompletedNCT01056029
GenSpera, Inc.Advanced Solid Tumors
Start: 2010-01-31End: 2013-08-31Target: 30Updated: 2015-12-10

Phase 2

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
WithdrawnNCT01734681
GenSpera, Inc.Prostate Cancer.
Start: 2013-05-31End: 2015-01-31Updated: 2014-02-19
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
CompletedNCT01777594
GenSpera, Inc.Advanced Adult Hepatocellular Carcinoma
Start: 2013-01-31End: 2015-03-31Updated: 2016-08-23
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
CompletedNCT02067156
GenSpera, Inc.Glioblastoma Multiforme
Start: 2014-02-28End: 2017-02-28Updated: 2024-05-21
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
CompletedNCT02381236
GenSpera, Inc.Prostatic Neoplasms
Start: 2016-02-29End: 2017-02-28Updated: 2017-02-24
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
CompletedNCT02607553
GenSpera, Inc.Clear Cell Renal Cell Carcinoma
Start: 2016-06-30End: 2017-02-28Updated: 2017-02-24
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
WithdrawnNCT02876003
GenSpera, Inc.Glioblastoma
Start: 2016-09-30End: 2020-10-31Updated: 2017-02-24

Unknown Phase

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
NCT02082691
Devalingam MahalingamHepatocellular Carcinoma
Updated: 2014-03-10

Related Papers

Clinical activity and correlative DCE-MRI imaging of G-202, a thapsigargin-based prostate-specific membrane antigen-activated prodrug, in progressive hepatocellular cancer.
Journal of Clinical Oncology2015-01-206 citations